FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
|Slideshows|July 22, 2020
- June digital edition 2020
- Volume 12
- Issue 6
Moncler Lunettes sunglass and eyeglass collection 2020
Author(s)Brooke Henson, Editor
The new eyewear collection from Moncler Lunettes satisfies the need for high performance glasses suited to outdoor life yet easily wearable in urban contexts.
Advertisement
Articles in this issue
over 6 years ago
Telehealth success hinges on better toolsover 6 years ago
Lactoferrin levels can diagnose dry eye diseaseover 6 years ago
Resolved cotton-wool spot leaves RNFL defect in its wakeover 6 years ago
Patients aren’t hearing contact lens care informationover 6 years ago
11 things my patient wished her previous OD had told herover 6 years ago
Proper documentation helps assure prior authorizationsover 6 years ago
What a practice owner would advise her younger selfover 6 years ago
OCT, OCTA show promise in screening for DRAdvertisement
Related to this article
For Maria Sampalis, OD, implementing AI isn't an excuse for practice owners to replace their staff with new technology; it should instead lift the burden of certain tasks to make for more patient visits.
Walline, American Academy of Optometry president, shares this year's conference attendance numbers, clinical pearls, and what he hopes to see in 2027.
Thomas Wong, OD, FAAO, details a session he presented alongside Ronald Gentile, MD, FACS, FASRS, at AAOpt 2026.
Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia.
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session.
A single Epioxa epi-on cross-linking treatment sustained a 1.9 D Kmax improvement through three years in keratoconus, with no serious adverse events reported.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
The screen time question: What to ask and when to look deeper
2
AAOpt 2026: Current controversies in macular hole diagnosis, management
3
AAOpt 2026: Jeffrey Walline, OD, PhD, on his conference takeaways
4
FAQ: What clinicians should know as SYD-101 heads to FDA advisory committee
5